NCT03104595已完成1 期
EC-18 for Management of Chemotherapy-Induced Neutropenia in Patients With Advanced BC Receiving Low Febrile Neutropenia Risk Chemotherapy: Dose-Escalation, Open-label, Trial to Assess Safety and Tolerability of EC-18
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 28
- 试验地点
- 3
- 主要终点
- Duration of Grade 4 neutropenia
研究概览
简要总结
To assess the safety and establish the dose to assess the pharmacokinetic activity following administration of EC-18 in patients with advanced breast cancer receiving low febrile neutropenia risk chemotherapy who are the candidates for second-line or higher combination therapy with doxorubicin and cyclophosphamide.
详细描述
This study will utilize a non-randomized, open-label 3 + 3 dose escalation design in which subjects will receive 500 mg, 1000 mg, 1500 mg, 2000 mg, 3000 mg and 4000mg of EC-18. The stepwise daily dosing by cohort was performed for 21 days (3 weeks)
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Sequential
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 19 Years 至 —（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Women ≥19 years of age
- •Subjects who have voluntarily signed the informed consent prior to the screening tests to participate in the study
- •Subjects who have been diagnosed as adenocarcinoma of the breast and relapsed after adjuvant or primary (neoadjuvant) chemotherapy, and was confirmed based on documented medical history to be candidates for second-line or higher combination chemotherapy with doxorubicin and cyclophosphamide to treat relapsed or metastatic disease.
- •Subjects with adequate function of major organs based on the following clinical laboratory values in the latest test performed within 28 days prior to IP dosing:
- •Neutrophil count (ANC): ≥1,500/mm3
- •Platelet count: ≥10.0×10^4/mm3
- •Hemoglobin: ≥9.0 g/dL
- •AST, ALT: ≤3.0 x ULN
- •Serum total bilirubin: ≤1.5 mg/dL
- •Serum creatinine: ≤1.5 mg/dL
- •Subjects whose Eastern Cooperative Oncology Group (ECOG) performance score is 0-
- •For women of child bearing potential, subjects should have willingness to use acceptable contraceptive methods during the entire clinical study period.
- •Subjects who are capable of understanding the overall procedure of the clinical study and are willing to participate in compliance with all test procedures.
排除标准
- •Subjects with active and inactive hepatitis, patients with history of HIV, or other uncontrolled infectious disease.
- •Subjects with a history of HIV positive or currently undergoing/received antiretroviral therapy, and subjects with a history of hepatitis B surface antigen positive, or current positive hepatitis C disease.
- •Subjects who received radiation therapy within 4 weeks prior to assignment to treatment group.
- •Subjects who have been diagnosed within 5 years with other types of cancer except for those who have been appropriately treated for superficial non-melanoma skin cancer or cervical intraepithelial neoplasia.
- •Subjects with a history of intolerance for granulocyte colony stimulating factor treatment
- •Subjects who are expected to show hypersensitivity to the IP or its ingredients
- •Subjects with a positive urine pregnancy test result at screening visit or before the first administration of the study drug
- •Subjects who took any other investigational product in other clinical study within 30 days prior to screening visit.
- •Clinically significant unstable medical abnormality; psychiatric disorder, chronic disease, alcohol or drug use disorder, or other significant biological, psychological, or social factor, which in the investigator's opinion, unfavorably affects the risk-benefit ratio of study participation or likely to affect study results.
- •Subjects with heart disease (i.e. congestive heart failure, arrhythmia, symptomatic coronary artery disease); Myocardial infarction within 6 months before initiation of the study.
- •Subjects with left ventricular ejection fraction (LVEF) < 50% at screening.
- •Significant neurological or psychiatric disorders including dementia or seizures.
- •Patients with dyslipidemia not controlled by drugs [based on LDL-C and TG levels for which treatment is recommended by the Korean dyslipidemia treatment guidelines and the U.S. National Cholesterol Education Program-Adult Treatment Panel III]
- •Uncontrolled diabetes mellitus (HbA1c >7%; if the level is confirmed after 6 months or longer treatment with oral hypoglycemic agents or insulin)
- •Subjects who have received systemic chemotherapy with doxorubicin to treat metastatic or recurrent breast cancer
- •Subjects with grade 2 or higher peripheral sensory neuropathy at screening visit or before the first dosing of the study drug
- •Subjects who have undergone significant gastrectomy along with intractable nausea and vomiting, chronic gastrointestinal disease, or clinically significant sequelae, which would interfere with proper absorption of the study drug
- •Subjects who administered systemic antibiotics within 14 days prior to administration of the study drug
- •Subjects whose cumulative dose of doxorubicin exceeded 240 mg/m2
- •Subjects who were currently receiving trastuzumab
研究组 & 干预措施
Cohort 1
Experimental
EC-18 500 mg
干预措施: EC-18 (Drug)
Cohort 2
Experimental
EC-18 1000 mg
干预措施: EC-18 (Drug)
Cohort 3
Experimental
EC-18 1500 mg
干预措施: EC-18 (Drug)
Cohort 4
Experimental
EC-18 2000 mg
干预措施: EC-18 (Drug)
Cohort 5
Experimental
EC-18 3000 mg
干预措施: EC-18 (Drug)
Cohort 6
Experimental
EC-18 4000 mg
干预措施: EC-18 (Drug)
结局指标
主要结局
Duration of Grade 4 neutropenia
时间窗: 15 days after starting chemotherapy
Complete blood count and absolute neutrophil count assessed daily to determine febrile neutropenia
次要结局
- Incidence of Grade 3-4 neutropenia(For 15 days after starting chemotherapy (except Day 3 and 4))
- Incidence of febrile neutropenia(For 15 days after starting chemotherapy (except Day 3 and 4))
研究者
研究点 (3)
Loading locations...
相似试验
已完成
1 期
Assessment of Single Doses of Oral Dexanabinol in Healthy SubjectsSafetyTolerabilityPharmacokineticsCancerNCT02054754e-Therapeutics PLC40
已完成
1 期
Pharmacokinetics, Pharmacodynamics Profile and Tolerance of P03277 in Healthy Subjects and Patients With Brain LesionsHealthy VolunteersBrain LesionNCT03603106Guerbet142
已完成
1 期
Safety, Tolerability, Pharmacokinetics of Single Rising Oral Doses of BI 1181181 in Healthy Male Volunteers, Including Investigation of the Effect of Food on the Bioavailability of BI 1181181HealthyNCT02044406Boehringer Ingelheim65
招募中
1 期
A Multicenter, Phase 1/1b, Open-Label, Dose-Escalation Study of ABBV-399, an Antibody Drug Conjugate, in Subjects With Advanced Solid Tumors-JPRN-jRCT2080225128-6
已完成
1 期
Single Rising Dose Study of BI 135585 XX in Health Asian Male Volunteers.HealthyNCT01291732Boehringer Ingelheim48